1554015-60-9

Downstream Products

• 1554015-78-9 C₃₀H₃₄ClN₇OS 
• 1554014-50-4 1'-neopentyl-1-(2-(5-phenyl-1,3,4-thiadiazol-2-ylamino)phenyl)-4-(trifluoromethyl)spiro[indoline-3,4'-piperidin]-7-ol 
• 1554015-72-3 N-(2-(7-methoxy-1'-neopentyl-4-(trifluoromethyl)spiro[indoline-3,4'-piperidine]-1-yl)phenyl)-5-phenyl-1,3,4-thiadiazol-2-amine 
• 1554015-75-6 N-(2-(4-chloro-7-methoxy-1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)hydrazinecarbothioamide 
• 1554015-71-2 1-(2-isothiocyanatophenyl)-7-methoxy-1'-neopentyl-4-(trifluoromethyl)spiro[indoline-3,4'-piperidine] 
• 1609548-38-0 C₃₇H₄₄F₃N₅OS 
• 1609548-37-9 C₃₄H₃₅F₆N₅OS 
• 1554015-40-5 methyl 1-(2-{[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]amino}phenyl)-1'-neopentyl-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-4-carboxylate 
• 1554015-43-8 1-(2-{[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]amino}phenyl)-1'-neopentyl-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-4-carbonitrile 
• 1554014-53-7 1-(2-(5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-ylamino)phenyl)-1'-neopentyl-4-(trifluoromethyl)spiro[indoline-3,4'-piperidin]-7-ol 
• 1554014-54-8 1'-neopentyl-4-(trifluoromethyl)-1-(2-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-ylamino)phenyl)spiro[indoline-3,4'-piperidin]-7-ol 
• 1557209-59-2 4-nitrophenyl 2-(7-methoxy-1'-neopentyl-4-(trifluoromethyl)spiro[indoline-3,4'-piperidine]-1-yl)phenylcarbamate 

Relevant academic research and scientific papers

AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used as medicaments.

7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of Ρ2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.